Show threadVictoria Stuart 🇨🇦 🏳️‍⚧️Aug 8, 2023

... cont'd 1/2

* regulator protein CMTM6 inhibits degradation of both CD58 (stimulates T cell activity) & cell surface protein PD-L1 (inhibits T cell activity)
* CD58 & PD-L1 compete for binding to regulator protein CMTM6
* tumor cell that express less CD58 free up more CMTM6 to stabilize PD-L1

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity
https://www.sciencedirect.com/science/article/abs/pii/S1535610823001812
https://www.biorxiv.org/content/10.1101/2022.03.21.485049v1

* cancer immune evasion
...

#melanoma #CD58 #CMTM6 #PDL1

Victoria Stuart 🇨🇦 🏳️‍⚧️Aug 8, 2023

Cancer Cloaking Device Revealed
https://www.cancer.columbia.edu/news/cancers-cloaking-device-revealed
Discussion: https://news.ycombinator.com/item?id=37042790

* Malignant melanoma (skin cancer) deploys elegant molecular mechanism to evade natural immune responses, therapies
* immune system eliminates abnormal cells; cancers can elude it
* tumor cells that suppressed cell surface protein CD58 expression better at escaping immune surveillance
* hinted at how melanomas might be hiding f. T cells
...

#cancer #melanoma #CD58 #CMTM6 #PDL1 #Tcells #ImmuneSystem

Cancer’s Cloaking Device Revealed

Research from Dr. Ben Izar suggests new strategies for attacking malignant melanoma and possibly other types of cancer.

Herbert Irving Comprehensive Cancer Center (HICCC) - New York